Definium Therapeutics, Inc. (DFTX)

Market Cap	1.71B +225.4%
Revenue (ttm)	n/a
Net Income	-168.10M
EPS	-1.98
Shares Out	98.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111,640
Open	17.60
Previous Close	17.90
Day's Range	17.54 - 17.77
52-Week Range	4.70 - 18.70
Beta	2.62
Analysts	Strong Buy
Price Target	33.00 (+90.42%)
Earnings Date	Mar 5, 2026

About DFTX

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: DFTX
• Website: https://definiumtx.com

Analyst Summary

According to 2 analysts, the average rating for DFTX stock is "Strong Buy." The 12-month stock price target is $33.0, which is an increase of 90.42% from the latest price.

Price Target

$33.0

(90.42% upside)

Analyst Consensus: Strong Buy